Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-977X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report ; volume:5 ; number:1 ; day:11 ; month:5 ; year:2018 ; pages:1-4 ; date:12.2018
Drug safety - case reports ; 5, Heft 1 (11.5.2018), 1-4, 12.2018
- Urheber
-
Farhat, Lara
- Beteiligte Personen und Organisationen
-
Dara, Jasmeen
Duberstein, Susan
De, Aliva
SpringerLink (Online service)
- DOI
-
10.1007/s40800-018-0087-y
- URN
-
urn:nbn:de:101:1-2018071521114730800030
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Farhat, Lara
- Dara, Jasmeen
- Duberstein, Susan
- De, Aliva
- SpringerLink (Online service)
Ähnliche Objekte (12)
Effectiveness of rituximab in neuromyelitis optica: a meta-analysis
Neuromyelitis optica
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)
Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder
The history of neuromyelitis optica
The history of neuromyelitis optica
Schwannzell-Remyelinisierung bei Neuromyelitis optica
Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate
Use of rituximab and risk of re-hospitalization for children with neuromyelitis optica spectrum disorder
Ergebnisse der Cortisonbehandlung bei Neuromyelitis optica
The Gut Microbiome in Neuromyelitis Optica
Effectiveness of rituximab in neuromyelitis optica: a meta-analysis
Neuromyelitis optica
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)
Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder
The history of neuromyelitis optica
The history of neuromyelitis optica
Schwannzell-Remyelinisierung bei Neuromyelitis optica
Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate
Use of rituximab and risk of re-hospitalization for children with neuromyelitis optica spectrum disorder
Ergebnisse der Cortisonbehandlung bei Neuromyelitis optica
The Gut Microbiome in Neuromyelitis Optica
Effectiveness of rituximab in neuromyelitis optica: a meta-analysis
Neuromyelitis optica
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)
Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder
The history of neuromyelitis optica
The history of neuromyelitis optica
Schwannzell-Remyelinisierung bei Neuromyelitis optica
Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate
Use of rituximab and risk of re-hospitalization for children with neuromyelitis optica spectrum disorder
Ergebnisse der Cortisonbehandlung bei Neuromyelitis optica